Cryopreserved or fresh alloHCT graft lessons learned from the COVID19 pandemic
May 25, 2023
Description
At the start of the COVID-19 pandemic, most global donor registries mandated cryopreservation of products for allogeneic hematopoietic cell transplantation (alloHCT) to ensure patient safety and the timeliness of care delivery. During this webinar, expert panelists share research findings from the COVID-19 pandemic that provide a deeper understanding of the impact of graft cryopreservation on alloHCT patient outcomes.
Two transplant center physician panelists discuss use cases for cryopreservation, how their selection strategies have evolved since the pandemic and their process for choosing cryopreserved versus fresh grafts for alloHCT.
Learning Objectives
- Recent research on the impacts of using cryopreserved grafts in alloHCT
- Lessons learned about cryopreservation during the COVID-19 pandemic
- Current and evolving transplant center use cases for selecting cryopreserved vs. fresh grafts
- Considerations for transplant clinical decision making and protocols related to cryopreservation
Target Audience
Coordinators, physicians, medical directors and BMT fellows at transplant centers; HLA lab directors
Speakers
Steven Devine, MD (moderator)
Chief Medical Officer, NMDP
Senior Scientific Director
CIBMTR®-NMDP
Heather Stefanski, MD, PhD
Vice President of Medical Services
NMDP
Alexandra Gomez Arteaga, MD
Assistant Professor of Medicine in the Division of Hematology and Medical Oncology
Weill Cornell Medicine/New York-Presbyterian Hospital
Taiga Nishihori, MD
Senior Member; Medical Director — BMT Program
Moffitt Cancer Center